Stay updated on Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page.
Latest updates to the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page
- Check4 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.0%
- Check12 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for those interested in joining the study, along with a reference to the Contacts and Locations section.SummaryDifference1%
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe website has been updated from version 2.12.1 to 2.12.2.SummaryDifference0.0%
- Check47 days agoChange DetectedThe website has been updated from version v2.11.2 to v2.12.1.SummaryDifference0.1%
- Check79 days agoChange DetectedNew results have been posted detailing various efficacy endpoints such as Progression-Free Survival (PFS), Overall Survival (OS), and Objective Response Rate (ORR) based on RECIST v1.1 assessments, alongside patient-reported outcomes and adverse event data, marking significant updates in the study's findings.SummaryDifference56%
- Check87 days agoChange DetectedThe website has been updated to Revision v2.11.0, while the previous version v2.10.5 has been removed, along with a notice regarding delays in displaying study record information.SummaryDifference0.5%
Stay in the know with updates to Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page.